TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc. (ARCH:CA), (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development ...
In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in ...
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in ...
Pangea Natural Foods Inc. (CSE:PNGA) (OTC: PNGAF) (" Pangea " or the " Company"), is excited to announce that its wholly ...
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, ...
As peptides gain more traction in things like the cosmetic industry, it's no surprise that they are being covetted for their uses in other areas of health. What other areas can they help with? Things ...
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback